Rainy River Resources Ltd. ("Rainy River" or the "Company" (RR.TSX)) is pleased to announce that it has made significant progress on key aspects of the development of its namesake Rainy River Gold Project ("RRGP" or "Project").  Details are provided below:

Technical:

Nordion Inc. (NDN.TO) (NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, announced that it has entered into an agreement to divest its Targeted Therapies business to BTG plc (BTG.L) (“BTG”), an international specialist healthcare company based in London, United Kingdom, for a cash purchase price of US$200 million. Net of cash taxes and transaction costs, Nordion expects to realize approximately US$185 million on closing. The transaction is anticipated to be completed by the end of June 2013.

Nordion manufactures and commercializes TheraSphere®, a targeted liver cancer therapy, the sole product in its Targeted Therapies business. Under the terms of the transaction agreements, BTG is expected to acquire TheraSphere and Nordion has agreed to continue manufacturing TheraSphere under a Manufacturing and Support Agreement with a contract term of three years, plus a two-year extension at BTG’s option. Approximately 40 Nordion employees are expected to join BTG following the completion of this transaction, which is subject to customary closing conditions and approval by BTG shareholders.

Copper Mountain Mining Corporation (TSX:CUM ) (the "Company" or "Copper Mountain") announces that further to the Company's news release of May 17, 2013, the damaged SAG mill transformer was replaced late Friday and the mill was back in operation by 6 pm Friday May 17, 2013.  Site maintenance personnel were able to successfully replace the damaged transformer with identical transformers from Ball Mill #1.  Operations over the long weekend with the SAG mill and one ball mill was better than forecast and operated at an average rate of 1,100 tpoh or an average of 25,400tpd.

Cleantech Solutions International, Inc. ("Cleantech Solutions" or "the Company") (CLNT), a manufacturer of metal components and assemblies, primarily used in the wind power, solar and other clean technology industries and dyeing and finishing equipment to the textile industry, today announced that it has become a certified supplier of components to China Petroleum and Chemical Corporation (Sinopec) and China National Petroleum Corporation (CNPC).

In May 2013, the Company delivered protoypes to Sinopec and CNPC of forged flanges and pipes, which are components used in oil and natural gas onshore and offshore drilling and refinery equipment. The Company's subsidiary, Wuxi Fulland Wind Energy Equipment Co., Ltd., has also received the necessary third party certifications, stating that its flanges and pipes are in conformity with the applicable standards in regard to axis shape, circular shape, tubular shape and forging processing.

Provides Important Foundation as Company Advances European Commercial Plans for ARIKACE to Treat Lung Infections in Cystic Fibrosis Patients

Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat patients battling serious lung diseases in orphan indications that are often life-threatening, today announced that the European Patent Office intends to grant E.U. Patent No. 1909759 for ARIKACE® (liposomal amikacin for inhalation). Once granted, the composition of matter patent provides exclusivity in any of the European Patent Office's member states where Insmed chooses to file at least through July 19, 2026. The Company's liposomal amikacin for inhalation is in clinical development to treat cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections and patients with nontuberculous mycobacteria (NTM) lung infections.

Asanko Gold Inc. ('Asanko' or the 'Company') (TSX:AKG)(NYSE MKT:AKG) is pleased to announce that the Pre-Feasibility Study ('PFS') for its flagship Esaase Gold Project in Ghana, West Africa ('Esaase' or the 'Project'), has confirmed the technical and economic viability of the Project. All currency in this news release is quoted in United States Dollars unless otherwise stated.

Highlights of the PFS (based on $1,400 per ounce gold price) are, as follows:

Synacor to Showcase Cloud ID Social Login with Google+ Sign-In for TV Everywhere Sites and Apps, Google I/O, May 15-17, Moscone West Convention Center, San Francisco, Calif.

Synacor Inc. (SYNC), the leading provider of next-gen startpages, award-winning TV Everywhere solutions, and cloud-based Identity Management (IDM) services, across multiple devices for cable, satellite, telecom and consumer electronics companies, will demo Cloud ID Social Login with Google+ and advanced TV Everywhere technologies in the Developer Sandbox at Google I/O, May 15-17, Moscone West Convention Center in San Francisco, Calif. Developers and technologists will discuss with Synacor how Social Login, recently named as a TMC Cable Spotlight Product of the Year, was built to break down TV Everywhere barriers, and how they can integrate similar technologies for their customers.

Nanosphere, Inc. (NASDAQ: NSPH)

Nanosphere, Inc. (NASDAQ: NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today it has signed a distribution and collaboration agreement with Hitachi High-Technologies Corporation (Hitachi High-Tech). The agreement grants Hitachi High-Tech exclusive rights to market Nanosphere products in Japan. As well, the two companies intend to collaborate on assay and platform development.

 Soltoro Ltd. (TSX VENTURE:SOL) participates in discoveries and advancements at Coyote through its ~15% equity holding in Argentum Silver Corp. (TSX VENTURE:ASL) and its retained 3% N.S.R. royalty interest in the Coyote property.

Argentum Silver has received an independent study and evaluation on a 600 metre portion of the El Tajo vein at the Coyote Silver Project in Jalisco, Mexico. The report states a minimum target potential of between 482,000 and 876,000 tonnes at a cut-off grade between 50 and 20 grams per tonne, for a potential of between 4,000,000 and 5,000,000 ounces silver.

Theravance to receive $1.0 billion upfront payment upon closing; Elan to receive a 21% participation interest in potential future royalty payments associated with four respiratory programs

Theravance, Inc. (NASDAQ: THRX) and Elan Corporation, plc (NYSE: ELN) today announced that they have entered into a royalty participation agreement wherein Elan will purchase a participation interest in potential future royalty payments related to four respiratory programs partnered with GlaxoSmithKline plc (GSK): RELVAR™ ELLIPTA™/BREO™ ELLIPTA™, ANORO™ ELLIPTA™, MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist) monotherapy (GSK961081, or MABA '081), and vilanterol (VI) monotherapy. Under the terms of the agreement, Elan will make a one-time cash payment of $1.0 billion to Theravance in exchange for a 21% participation interest in the potential future royalty payments from the four programs when, as and if received by Theravance.

Dataram Corporation [NASDAQ: DRAM]), a leading international manufacturer of computer memory and software products, announced an expanded partnership with Advanced Micro Devices, Inc. (AMD) as described in a recent press release. This partnership includes Dataram Corporation as an AMD memory-manufacturing partner to produce AMD’s new Gamer Series memory. Dataram and AMD previously announced a formal agreement for Dataram to develop an AMD-branded version of Dataram’s popular RAMDisk software. Gamer Series memory is compatible with AMD and Intel platforms, supporting both AMP and XMP memory profiles. The memory is being sold and marketed under the AMD Radeon™ Memory brand, targeting gaming enthusiasts interested in exceptional memory performance and reliability.

The HeartCheck PEN ECG device is the first to utilize the patent pending SMART Monitoring technologies to enable/unlock a consumer medical devices to record, display, transmit and receive bio-signals and images.

CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company"), a global medical provider of electrocardiogram ("ECG") acquisition and management software solutions, today confirmed it has filed for U.S. and Canadian patents for use of their proprietary technologies in the automated, software enabled and server based unlocking of over-the-counter ("OTC"), consumer based, bio-monitoring devices. Under the U.S and Canadian patents, filed on May 6, 2013 and May 8, 2013 respectively, the Company will be permitted to apply the statement "Patent Pending SMART Monitoring Technologies" in its corporate materials until the application process has been completed.

-Medicago Ready to Collaborate with Authorities to Further Study the Potential of this Vaccine to Protect Against H7N9-

Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has successfully produced a new VLP vaccine candidate  for the H7N9 virus that is responsible for the current influenza outbreak in China.

Groundbreaking Results from University of California, San Francisco (UCSF) Clinical Validation Study Presented at American Urological Association (AUA) Annual Meeting First-of-its-Kind, Biopsy-Based Test Developed and Validated in Seven Studies Including More Than 1,100 Patients

Genomic Health, Inc. (GHDX) is making its Oncotype DX® prostate cancer test available to physicians and their patients today following the presentation by the University of California, San Francisco (UCSF) of a positive clinical validation study at the 2013 American Urological Association (AUA) Annual Meeting in San Diego. 

Adasuve® (loxapine) inhalation powder is approved in the U.S. for the acute treatment of agitation associated with schizophrenia and bipolar disorder

Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd (TEVA), and Alexza Pharmaceuticals, Inc. (ALXA) announced today that the companies have entered into an exclusive U.S. license and supply agreement for ADASUVE (loxapine) inhalation powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Teva will be responsible for all U.S. commercial and clinical activities for ADASUVE, including U.S. post-approval clinical studies, and has gained rights to conduct additional clinical trials of ADASUVE for potential new indications in neurological disorders. Alexza will be responsible for manufacturing and supplying ADASUVE to Teva for commercial sales and clinical trials.

Cayden Resources Inc. (TSX VENTURE:CYD) ("Cayden" or the "Company") is pleased to provide a corporate update to its shareholders.

Cash position and sustainability

The Company currently has a strong cash position with over two years of operating capital. The current treasury including near-term receivables is approximately $15 million and Cayden is budgeting to have in excess of $9 million in the treasury in December, after the 2013 drill programs and property payments are completed.

Cayden has the unique opportunity to obtain additional non-dilutive funding with the potential future sale of its Las Calles concession. The concession represents a strip of land, located in between the operating Los Filos and El Bermejal pits that make up Goldcorp's (TSX-G) Los Filos mine.

FIRST MAJESTIC SILVER CORP. (TSX:FR)(NYSE:AG)(FRANKFURT:FMV) (the "Company" or "First Majestic") is pleased to announce that the expansion that commenced at the La Guitarra Silver Mine in November 2012 is now complete. The processing plant's capacity increased by 40% to 500 tpd from 350 tpd and commercial production is expected to reach 500 tpd during the month of May.

The construction of the new circuit was completed on budget and has been operating since April 24, 2013, without disrupting operations in the old 350 tpd circuit. This new circuit, resulting from the installation of a new ball mill and new flotation cells, is anticipated to produce approximately 1.2 million ounces of silver equivalent annually, representing over one million ounces of pure silver plus a modest amount of gold.

Through Synacor's Startpages, Verizon FiOS TV Subscribers Have Access to a Variety of Programming From HBO, Showtime, SyFy, Telemundo, NBC and More

Synacor, Inc. (SYNC), leading provider of next-gen startpages, TV Everywhere solutions and cloud-based Identity Management (IDM) services across multiple devices for cable, satellite, telecom and consumer electronics companies, today announced it has expanded its relationship with Verizon to offer the company's nearly 5 million FiOS TV subscribers access to TV shows and movies from one online destination. The My Verizon website now includes a simple search and discovery experience, easy authentication, and the ability to log in just once.

-- Deal with Major South American Oil Producer Expands Redline's Global Footprint--

Redline Communications (www.rdlcom.com Group Inc. TSX: RDL), a leading provider of broadband wireless solutions for machine-to-machine (M2M) communications, today announced that their rugged industrial wireless system was chosen to create a wireless infrastructure for a major oil producer in South America.

As in other parts of the world, the oil & gas industry in South America has turned to Enhanced Oil Recovery (EOR) techniques to increase production, safety, and to reduce the environmental impact in their mature oil fields. 

Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced the results of a five-week proof of concept clinical study of TT-401 in type 2 diabetic and obese non-diabetic subjects.  In the study, TT-401 a once-weekly administered peptide, demonstrated significant improvements in glycemic control and reductions in body weight.

The study enrolled diabetic patients at five dosing levels and non-diabetic obese patients at one dose level.  All dosing cohorts received five doses over a five week period.  Diabetic patients were on stable doses of metformin.  At the end of the treatment period, TT-401-treated patients in the three highest dose groups experienced statistically significant reductions in mean fasting plasma glucose relative to placebo.